相似文献
1
Preface of the Special Issue: "Peritoneal Surface Malignancies (PSM): The SICO (Italian Society of Surgical Oncology) PSM-Oncoteam Experience, Result Analysis, and Studies' Purpose".特刊前言：“腹膜表面恶性肿瘤（PSM）：意大利外科肿瘤学会（SICO）PSM肿瘤治疗团队的经验、结果分析及研究目的”
Cancers (Basel). 2021 Dec 20;13(24):6387. doi: 10.3390/cancers13246387.
2
Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey.意大利乳腺癌新辅助全身治疗：意大利外科肿瘤学会（SICO）乳腺肿瘤团队调查。
Eur J Surg Oncol. 2018 Aug;44(8):1157-1163. doi: 10.1016/j.ejso.2018.03.018. Epub 2018 Mar 31.
3
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer.首届关于卵巢癌腹膜转移癌的细胞减灭术和腹腔热灌注化疗的意大利循证共识会议。
Tumori. 2017 Nov 23;103(6):525-536. doi: 10.5301/tj.5000623. Epub 2017 Apr 20.
4
Predictive value of peritoneal cancer index for survival in patients with mucinous peritoneal malignancies treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a single centre experience.腹膜癌指数对接受细胞减灭术和腹腔热灌注化疗治疗的黏液性腹膜恶性肿瘤患者生存的预测价值：单中心经验。
Int J Hyperthermia. 2018 Aug;34(5):512-517. doi: 10.1080/02656736.2017.1351627. Epub 2017 Jul 26.
5
Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.结直肠或阑尾肿瘤所致腹膜表面恶性肿瘤患者的细胞减灭术及腹腔内热灌注化疗应用指南。
Curr Oncol. 2015 Apr;22(2):e100-12. doi: 10.3747/co.22.2058.
6
Functional biomaterials for the diagnosis and treatment of peritoneal surface malignancies.用于腹膜表面恶性肿瘤诊断和治疗的功能性生物材料。
Smart Med. 2023 Jul 13;2(3):e20230013. doi: 10.1002/SMMD.20230013. eCollection 2023 Aug.
7
Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.评估细胞减灭术和 HIPEC 治疗腹膜表面恶性肿瘤：384 例连续病例分析。
Langenbecks Arch Surg. 2019 Aug;404(5):527-539. doi: 10.1007/s00423-019-01805-x. Epub 2019 Aug 3.
8
Treatment principles for peritoneal surface malignancies.腹膜表面恶性肿瘤的治疗原则。
Minerva Chir. 2016 Apr;71(2):124-45. Epub 2016 Feb 5.
9
The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers.意大利外科肿瘤学会（SICO）关于罕见癌症转诊中心最低要求的调查。
Updates Surg. 2016 Dec;68(4):321-323. doi: 10.1007/s13304-016-0376-x. Epub 2016 Jun 16.
10
The italian society of surgical oncology (SICO).意大利外科肿瘤学会（SICO）
J Surg Oncol. 2000 May;74(1):1. doi: 10.1002/1096-9098(200005)74:1<1::aid-jso1>3.0.co;2-3.
本文引用的文献
1
The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI).PRODIGE 7对目前全球结直肠癌腹膜转移的CRS-HIPEC治疗实践的影响：一项基于网络的调查以及国际腹膜表面肿瘤学组（PSOGI）2021年声明
Eur J Surg Oncol. 2021 Nov;47(11):2888-2892. doi: 10.1016/j.ejso.2021.05.023. Epub 2021 May 13.
2
The Chicago Consensus on Peritoneal Surface Malignancies: Standards.《芝加哥腹膜表面恶性肿瘤共识：标准》。
Ann Surg Oncol. 2020 Jun;27(6):1743-1752. doi: 10.1245/s10434-020-08325-9. Epub 2020 Apr 13.
3
Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM).结直肠腹膜转移患者的转诊途径和结局。
Eur J Surg Oncol. 2019 Dec;45(12):2310-2315. doi: 10.1016/j.ejso.2019.07.008. Epub 2019 Jul 4.
4
Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review.腹膜转移的预防与治疗：综述
Indian J Surg Oncol. 2019 Mar;10(1):3-23. doi: 10.1007/s13193-018-0856-1. Epub 2019 Jan 3.
Zotero 插件